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6-Anilinouracils are selective inhibitors of DNA polymerase III, the enzyme required for the replication of
chromosomal DNA in gram-positive bacteria (N. C. Brown, L. W. Dudycz, and G. E. Wright, Drugs Exp. Clin.
Res. 12:555–564, 1986). A new class of 6-anilinouracils based on N-3 alkyl substitution of the uracil ring was
synthesized and analyzed for activity as inhibitors of the gram-positive bacterial DNA polymerase III and the
growth of gram-positive bacterial pathogens. Favorable in vitro properties of N-3-alkyl derivatives prompted
the synthesis of derivatives in which the R group at N-3 was replaced with more-hydrophilic methoxyalkyl and
hydroxyalkyl groups. These hydroxyalkyl and methoxyalkyl derivatives displayed Ki values in the range from
0.4 to 2.8 mM against relevant gram-positive bacterial DNA polymerase IIIs and antimicrobial activity with
MICs in the range from 0.5 to 15 mg/ml against a broad spectrum of gram-positive bacteria, including
methicillin-resistant staphylococci and vancomycin-resistant enterococci. Two of these hydrophilic derivatives
displayed protective activity in a simple mouse model of lethal staphylococcal infection.
The escalating incidence of infection with multiple-antibiot-
ic-resistant forms of low G1C content gram-positive bacteria
is a major and rapidly growing clinical problem (20). In an
effort to address this problem, we have sought to identify a new
gram-positive-bacterium-specific antimicrobial target and to
develop selective “bullets” to hit it. The target we have selected
is DNA polymerase III (pol III), the product of the polC gene
(10, 13, 15, 16).
We have targeted the polC-specific pol III for three reasons.
First, it is absolutely essential for the replication of the host
chromosome of the low G1C content gram-positive bacteria;
when its action is blocked, chromosomal DNA fails to replicate
and the bacterial host dies (5, 6, 10, 15, 25). Second, this pol III
is a target whose essential structure is strongly conserved in
a broad group of relevant low G1C content gram-positive
pathogens, including Staphylococcus, Streptococcus, Enterococ-
cus, and Mycoplasma (2, 13). Third, the active-site domain of
this enzyme incorporates a unique receptor which renders it
specifically susceptible to the small molecule inhibitors of
the 6-anilinouracil (AU) class (see references 6 and 7 and
structure shown in Fig. 1A, below). It is this AU class of pol
III-specific inhibitors which we seek to develop as gram-posi-
tive-bacterium-selective antimicrobials. The results described
below summarize the progress we have made in this effort.
MATERIALS AND METHODS
Determination of water solubility. A known mass of pure, dried compound was
dissolved in dilute NaOH at pH 12.0. The solution was then neutralized to pH 7.0
with 0.1 N HCl for determination of the extinction coefficient at the absorbance
maximum. To determine water solubility, an excess of each compound was
stirred in deionized water (pH 7.0) at 25°C for 1 h. After removal of undissolved
compound by filtration, the absorbance of the solution at the absorbance max-
imum was determined and used to calculate the concentration of the compound
remaining in solution. Each reported value is the mean of three independent
experiments.
Bacterial strains and media. Bacillus subtilis was the standard penicillin-sen-
sitive laboratory strain, BD54 (16). Enterococcus faecalis, Enterococcus faecium,
and Staphylococcus aureus were clinically derived strains which were typed and
kindly provided by Gary Doern, University of Massachusetts Medical Center.
Unless noted otherwise, bacteria were grown in Luria broth medium consisting
of 0.5% yeast extract (Difco), 1% tryptone (Bacto-tryptone; Difco) and 0.5%
NaCl in deionized water.
Inhibitors. N-3-substituted AUs were synthesized, purified, and analyzed as
described in reference 19. 6-(p-Hydroxyphenylazo)uracil (HPUra) and other
AUs were synthesized and purified as described (26).
Enzymes. The pol IIIs of B. subtilis and S. aureus were homogeneous recom-
binant proteins expressed and prepared as described (12, 18). E. faecalis pol III
was fraction V purified from ATCC 8043 as described by Barnes and Brown (1).
The dnaE-encoded E. coli pol III was the recombinant form of the reconstitut-
ed core enzyme (alpha-epsilon-theta [14]) and was kindly provided by Charles
McHenry, University of Colorado, Denver. Immunopurified calf thymus DNA
pol alpha was kindly provided by Ulrich Hu¨bscher of the University of Zu¨rich-
Irchel, Zu¨rich, Switzerland.
Determination of MIC. Log-phase bacterial cultures were diluted to a con-
centration of ;105 CFU per ml in Luria broth, and samples of this suspension
were distributed to the wells of a 48-well microassay plate. Each compound was
dissolved in dimethylsulfoxide (DMSO) and added to one well at a concentration
of 200 mM. The contents of this well were then serially diluted, twofold each
time, through seven wells, to produce a series of eight wells containing 0.5 ml of
suspension and compound at the following successive concentrations: 200, 100,
50, 25, 12.5, 6.25, 3.125, and 1.5625 mM. All wells, including controls incubated
in the absence of inhibitors, contained 1% DMSO. DMSO at this concentration
did not significantly affect the growth of any of the test organisms. Plates were
incubated for 24 h at 37°C and read by visual inspection of the wells. MIC was
defined as the lowest concentration of inhibitor at which bacterial growth was not
visually apparent. Reported values are the median values for three experiments.
MICs were converted from micromolar concentrations to micrograms per mil-
liliter for tabulation.
Bactericidal activity. Each inhibitor was dissolved in sterile DMSO and diluted
100-fold into Mueller-Hinton broth (MHB; Difco) containing log-phase methi-
cillin-sensitive S. aureus (MSSA) (Smith strain) at a concentration of ;106 CFU
per ml. The control culture contained only 1% DMSO. The cultures were
incubated at 37°C, and at intervals during a 24-h period, samples were removed,
diluted extensively in sterile MHB, and plated on Luria broth-based agar plates
to determine the numbers of CFU.
DNA polymerase activity. DNA polymerases were assayed by using activated
calf thymus DNA and the basic method described in reference 1. Briefly, enzyme
was added to buffered solution containing Mg21, dithiothreitol, glycerol, satu-
rating concentrations of activated calf thymus DNA, dATP, dCTP, dTTP, and
[3H]dTTP, and appropriate concentrations of inhibitor included as a dilution of
a stock solution in DMSO. Assay mixtures were incubated at 30°C for 10 min,
reactions were stopped with cold trichloroacetic acid, and mixtures were filtered
to capture the cold acid-insoluble 3H-labeled DNA. The filters were washed in
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turn with cold trichloroacetic acid and ethanol and then dried. The incorporated
radioactivity was measured by scintillation counting of the dried filters as de-
scribed (1). Apparent inhibitor constants (Kis) of the AUs were determined
directly by truncated assay in the absence of dGTP as described by Wright and
Brown (23). Each reported value is the average for three independent experi-
ments. The average standard deviation for the values presented was 617.4%.
Assay for protection against lethal staphylococcal infection in vivo. This assay
was performed by the Pharmacology Services Laboratory of MDS Panlabs, Inc.
Female Swiss-Webster mice (20 g) were infected with a single intraperitoneal
injection of MSSA (ATCC Smith strain; 0.5 ml in physiological saline; 4 3 107
CFU/mouse), and 15 min thereafter, mice in each group of ten infected animals
were injected intraperitoneally once with one of the following solutions: (i) 0.1 ml
of physiological saline (vancomycin vehicle control); (ii) 0.1 ml of vancomycin (4
mg/ml in physiological saline; dose, 20 mg/kg of body weight); (iii) 0.1 ml of AU
vehicle control (10% DMSO–90% peanut oil); or (iv) 0.1 ml of 10% DMSO–
90% peanut oil containing the relevant N-3-substituted AU at a concentration
sufficient to give a dose of either 5 or 10 mg/kg. Following injection, each group
of ten animals was monitored for survival over a 3-day period.
Assay of DNA and RNA synthesis in B. subtilis BD54. At time zero [3H]ade-
nine (7 3 105 cpm/pmol; final concentration, 0.1 mM) and inhibitor or inhibitor
diluent were added to a log-phase culture growing at 37°C in a minimal medium
(8) with a doubling time of 35 min. After 30 min, duplicate 1-ml samples were
removed to determine incorporation into alkali-soluble (RNA) and alkali-stable
(DNA) fractions of cold trichloroacetic acid-insoluble material as described
previously (4).
RESULTS AND DISCUSSION
Summary of the mechanism of action of AUs on the gram-
positive bacterial pol III. Although simple molecules, the AUs
have two distinct domains essential for their inhibitory action.
These are illustrated in Fig. 1A. One, the so-called base-pair-
ing domain, is comprised of three uracil-specific components—
the ring 1-NH, the 2-keto, and the 6-NH components. The
second, enzyme-specific, domain is contributed by an appro-
priately substituted aryl group at N-6. Although formally pyri-
midines, the AUs derive their capacity to inhibit pol III by
mimicking the guanine component of the purine 29-deoxyribo-
nucleoside triphosphate dGTP. As shown in Fig. 1B, the AUs
derive this property from the capacity of the unconventional
base-pairing domain to specifically form three hydrogen bonds
with the pyrimidine base cytosine. Fig. 1C summarizes how the
FIG. 1. Structures and mechanisms of action of AUs which selectively inhibit the gram-positive pol III. (A) Relevant domains of the AU molecule. (B) Equivalence
of the base-pairing domains of the guanine (left) and AU (right) molecules. (C) The AU molecule inhibits its pol III target by sequestering it into an inactive
DNA-drug-protein complex. PUR, purine; PYR, pyrimidine. (D) Structures of two relevant AUs, EMAU and TMAU.
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base-pairing and enzyme-specific domains of the AU molecule
cooperate to inhibit pol III as it tries to elongate the primer
terminus past a cytosine residue in the DNA template. The
base-pairing domain of the inhibitor forms hydrogen bonds
with the cytosine, and simultaneously, the enzyme-specific aryl
moiety binds to the enzyme’s unique aryl receptor. As a result,
the inhibitor sequesters the enzyme with high affinity into a
nonproductive ternary complex with template-primer (5, 9,
10).
Effect of alkyl substitution at N-3 on antibacterial and anti-
pol III activities of AUs. Among the AUs which we have syn-
thesized (5, 7, 23–26), two of the most potent, 6-(3-ethyl-4-meth-
ylanilino)uracil (EMAU) and 6-([3,4-trimethylene]anilino)
uracil (TMAU), contain alkyl groups in the 3 and 4 positions of
the anilino ring (Fig. 1D shows structures). Although TMAU
and EMAU were potent inhibitors of the gram-positive bacte-
rial pol III (26), they showed weak antibacterial activity, yield-
ing MICs of 9 to 18 mg/ml (Table 1). In an attempt to improve
their antibacterial activities, we developed structure-activity
relationships involving substituents at ring nitrogen 3 (see
numbering in Fig. 1B and D), the only position in the AU
molecule where nondestructive substitution is feasible (21).
The first structure-activity relationship to exploit N-3 alky-
lation was performed on the TMAU platform. It had two
components, one of which assessed antimicrobial potency and
the other of which assessed potency for enzyme inhibition. The
former utilized several strains of relevant gram-positive bacte-
ria, while the latter utilized purified pol IIIs derived from three
relevant gram-positive organisms—B. subtilis, S. aureus, and
E. faecalis.
Table 1 summarizes the relative antibacterial activities (i.e.,
MICs) of a series of N-3-substituted TMAUs. The MIC results
show that N-3 alkylation with up to three carbons generally
improved potency for all organisms relative to that of the
unsubstituted TMAU. The ethyl and allyl groups increased
potency, but larger groups, such as the butyl group, did not.
Derivatives with the largest substituents, hexyl and benzyl, had
considerably weaker activities than TMAU.
Table 2 summarizes the effect of N-3 alkylation of TMAU
on its potency against the three isolated pol IIIs. The results,
displayed as apparent inhibitor constants (Kis [23]), indicate
that potency increased with increasing size of the N-3 alkyl
chain, reached a maximum (.10-fold) with addition of the
butyl substituent, and diminished with addition of the larger,
hexyl group. Addition of the benzyl group had a decidedly
negative effect on anti-pol activity, reducing it 15- to 18-fold
relative to that for the unsubstituted TMAU.
To determine whether the effects of N-3 substitution on
TMAU were applicable more generally to another active AU
platform, we synthesized and tested the ethyl and allyl deriv-















E. coli XL1 Blue
(Stratagene)
TMAU -H 9 18 18 18 9 18 18 .49
-CH3 (methyl) 1 10 13 19 10 5 13 .51
-CH2CH3 (ethyl) 0.6 3 7 5 3 3 3 .54
-CH2CHACH2 (allyl) 0.7 5 7 5 7 4 5 .57
-(CH2)2CH3 (propyl) 4 21 21 21 21 11 21 .57
-(CH2)3CH3 (butyl) 1 22 22 22 15 7 22 .60
-(CH2)5CH3 (hexyl) .33 .33 .33 .33 .33 .33 .33 .65
-CH2C6H5 (benzyl) .33 .33 .33 .33 .33 .33 .33 .67
EMAU -H 9 18 18 18 18 18 5 .49
-CH2CH3 (ethyl) 0.4 3 10 10 5 1 5 .55
-CH2CHACH2 (allyl) 0.5 5 11 11 11 11 11 .57
a MICs are the medians of three independent experiments performed as described in the Materials and Methods section.
TABLE 2. Kis of N-3-substituted TMAUs and EMAUs against
the pol IIIs of B. subtilis, S. aureus, and E. faecalis
AU R group substitutedat N-3
Ki (mM)a
B. subtilis S. aureus E. faecalis
TMAU -H 1.20 1.59 1.22
-CH3 (methyl) 1.34 1.22 0.84
-CH2CH3 (ethyl) 0.31 0.38 0.31
-CH2CHACH2 (allyl) 0.38 0.54 0.24
-(CH2)2CH3 (propyl) 0.31 0.20 0.22
-(CH2)3CH3 (butyl) 0.09 0.10 0.09
-(CH2)5CH3 (hexyl) 0.24 0.42 0.14
-CH2C6H5 (benzyl) 21.4 36.1 17.6
EMAU -H 1.00 1.16 0.61
-CH2CH3 (ethyl) 0.12 0.22 0.07
-CH2CHACH2 (allyl) 0.21 0.32 0.19
a All Kis are the averages of three independent experiments performed as
described in the Materials and Methods section.
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atives of EMAU. The results are summarized in the bottom
three rows of Tables 1 and 2.
With respect to antibacterial activity (Table 1), ethyl or allyl
substitution of EMAU had essentially the same effect as it had
on TMAU, i.e., it increased potency against all organisms ex-
cept E. faecium. The effect of ethyl or allyl substitution was
most dramatic in the case of B. subtilis, increasing potency
approximately 20-fold. In all cases, the N-3 ethyl form of
EMAU (Et-EMAU) displayed slightly greater potency than
the allyl derivative. For the two strains of methicillin-resistant
S. aureus (MRSA) both the N-3 allyl form of EMAU and
Et-EMAU displayed potency less than twofold greater than
that of the unsubstituted EMAU molecule. For the other strains,
N-3 alkyl substitution increased potency from 2- to 18-fold.
Both N-3 substituents significantly increased the anti-pol III
potency of EMAU (Table 2), and with the exception of E.
faecalis pol III, the orders of relative potency were qualitatively
the same as those for the ethyl and allyl derivatives of TMAU
(Table 2). In the case of E. faecalis pol III, the respective
potencies of the ethyl and allyl forms did not demonstrate a
specific rank order. As anticipated, N-3 substitution also did
not apparently change the selectivity of the molecule (5) for
low G1C content gram-positive bacteria as evidenced by the
lack of significant inhibitory effect of high concentrations on
the growth of the gram-negative organism Escherichia coli (Ta-
ble 1, right column).
In sum, the above results indicated that N-3 substitution on
the AU platform can lead to increases in both the antibacterial
and anti-pol III activities of these gram-positive-bacterium-
selective inhibitors. This effect was apparently maximal with
N-3 ethyl and allyl substitutions. As expected for compounds
which putatively hit a novel target, the N-3 alkyl-substituted
AUs were essentially equivalent with respect to potency
against antibiotic-sensitive and antibiotic-resistant strains of
relevant gram-positive organisms.
Effects of hydrophilic N-3 substitution of EMAU. Given
their strong anti-pol III actions and their favorable in vitro
antimicrobial potencies, we attempted to assess Et-EMAU and
Et-TMAU for their capacities to prevent gram-positive bacte-
rial infection in mice and thus “prove principle” in vivo. How-
ever, their marginal aqueous solubilities (3 mM for Et-TMAU
and 6.3 mM for Et-EMAU; determined as described in the
Materials and Methods section) severely restricted their bio-
availabilities following either oral or parenteral administration
and therefore precluded their use for this purpose. To improve
water solubility and bioavailability, we focused on the EMAU
platform and proceeded to synthesize two N-3 hydroxyalkyl
forms, i.e., the 2-hydroxyethyl derivative, HE-EMAU, and the
3-hydroxypropyl derivative, HP-EMAU (19). As expected, the
water solubilities of both agents were increased significantly
compared to that of Et-EMAU. The aqueous solubility of
HE-EMAU was 32 mM, and that of HP-EMAU was 98 mM.
Even the respective methoxyalkyl intermediates from which
HE-EMAU and HP-EMAU were synthesized were more wa-
ter soluble than Et-EMAU (the water solubility of the 2-
methoxyethyl intermediate [ME-EMAU] was 23 mM, and that
of the 3-methoxypropyl intermediate [MP-EMAU] was 22 mM).
Table 3 summarizes the effects of the N-3 hydroxyalkyl and
methoxyalkyl substitutions on the antimicrobial activity of the
EMAU platform. These substituents all enhanced antibiotic
activity relative to that of EMAU; their MICs, with the excep-
tions of those for vancomycin-resistant E. faecalis (VRE; Table
1) and MSSA (Table 1), equalled or were better than those of
Et-EMAU. Significantly, the propyl derivatives, MP-EMAU
and HP-EMAU, were as active against the MRSA and VRE
strains as they were against the corresponding antibiotic-sen-
sitive strains, and like the alkyl-substituted derivatives, none of
these more-hydrophilic compounds was active against E. coli at
;60 mg/ml, the highest concentration tested (right column,
Table 3).
The anti-polymerase activities of the methoxyalkyl- and hy-
droxyalkyl EMAUs are summarized in Table 4. These substi-
tuents did not significantly change either the potency of the
EMAU derivative or its selectivity for the gram-positive bac-
terial pol III. All three gram-positive bacterial pol IIIs were















E. coli XL1 Blue
(Stratagene)
-(CH2)2OH (HE) 0.7 7 14 14 5 7 7 .58
-(CH2)2OCH3 (ME) 0.9 15 8 8 6 6 8 .61
-(CH2)3OH (HP) 0.9 6 8 8 6 6 6 .61
-(CH2)3OCH3 (MP) 0.5 6 6 6 3 3 6 .63
a MICs are the medians of three independent experiments performed as described in the Materials and Methods section.
TABLE 4. Inhibitor constants (Kis) of N-3 hydroxyalkyl




B. subtilisb S. aureusb E. faecalisb E. colib pol alphac
-(CH2)2OH (HE) 0.59 2.48 0.48 .160 .160
-(CH2)2OCH3 (ME) 0.58 2.82 0.46 .160 .160
-(CH2)3OH (HP) 0.73 2.10 0.61 .160 .160
-(CH2)3OCH3 (MP) 1.00 1.27 0.42 .160 .160
a All Kis are the averages of three independent experiments performed as
described in the Materials and Methods section.
b Denotes the DNA pol III of the indicated organism; see Materials and
Methods section for source.
c Derived from calf thymus; see Materials and Methods section for source.
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clearly sensitive to the four compounds, with S. aureus pol III
slightly less sensitive than the enzymes of B. subtilis and E. fae-
calis. In contrast, none of the four agents displayed significant
inhibitory activity against either the dnaE-specific gram-nega-
tive bacterial (E. coli) pol III or the mammalian (calf thymus)
replicative enzyme, pol alpha.
Bactericidal properties of the methoxyalkyl and hydroxyal-
kyl EMAUs. Our earlier studies of the effects of HPUra, the
prototype for the AUs, indicated that it was bactericidal for
E. faecalis (6). To determine if the N-3-substituted hydroxy-
alkyl and methoxyalkyl EMAUs also were bactericidal, time-
kill studies were conducted with the MSSA Smith strain which
was to be used (see below) to examine their abilities to protect
against in vivo infection. The results are summarized in Fig. 2.
As shown in panel A, the ethyl derivatives, HE-EMAU and
ME-EMAU, were bactericidal at 43 MIC, while at MIC both
of them permitted some cell replication. The two propyl com-
pounds, HP-EMAU and MP-EMAU (Fig. 2, panel B), were
clearly bactericidal at 43 MIC, while at MIC they were, at best,
bacteriostatic.
Preservation of other key properties of HPUra. In addition
to its bactericidal effect, HPUra has three well-documented
properties which characterize its antibacterial action (5, 6, 9,
10, 17, 25). The first is its spectrum. HPUra is active against
only low G1C content gram-positive eubacteria and Mycoplas-
matales (3) and thus has no significant effect on the growth of
gram-negative eubacteria, mammalian cells, or high G1C con-
tent gram-positive eubacteria such as Streptomyces and Myco-
bacterium (4). The second distinct property of HPUra is its
selectivity for replicative DNA synthesis. Administration of the
agent to an exponentially growing culture of a sensitive organ-
ism at concentrations up to 203 MIC completely inhibits the
synthesis of DNA with little or no effect on the synthesis of
RNA or other macromolecules (5, 6, 8). The third important
characteristic of HPUra is its target within the DNA replica-
tion machinery. It is absolutely specific for the polC-encoded
pol III enzyme that is unique to low G1C content gram-
positive eubacteria (10, 11, 13, 25). The active form of HPUra
has no inhibitory effect on a wide variety of prokaryotic and
eukaryotic polymerases—including the mammalian pol alpha
and the pol IIIs of gram-negative and high G1C content gram-
positive bacteria (4–6, 10, 11).
Considering their potential for further development as an-
tibiotics (see below), we sought to determine whether the latest
generation of soluble EMAUs (i.e., HE-EMAU, ME-EMAU,
HP-EMAU, and MP-EMAU) faithfully retained the HPUra-
like specificity for DNA replication and pol III target. We
assessed their pol III specificities by exploiting E. coli pol III
and calf thymus DNA pol alpha as relevant control enzymes.
As the results shown in the rightmost columns of Table 4
indicate, the four compounds displayed HPUra-like specificity;
none of them displayed significant activity against either of
these test enzymes.
We next sought to determine if the N-3 hydroxyalkyl- and
N-3 methoxyalkyl-EMAUs also conserve HPUra’s specificity
for DNA replication in the intact cell. To this end, we exploited
an experimental approach that we used previously to assess the
pol III and DNA replication specificities of N2-(3,4-dichloro-
benzyl)guanine, an even more distant guanine derivative of the
HPUra pharmacophore (4). The experiment compared the
effect of each agent at 100 mM with that of 100 mM HPUra on
the incorporation of [3H]adenine into RNA and DNA (see the
Materials and Methods section for experimental details). The
results, expressed as percent inhibition of 3H incorporation
into DNA:percent inhibition of 3H incorporation into RNA,
were as follows: HPUra control, 88%:6%; HE-EMAU, 85%:
5%; ME-EMAU, 88%:5%; HP-EMAU, 86%:8%; and MP-
EMAU, 89%:4%. In sum, these results strongly suggest that
the four hydrophilic N-3-substituted EMAUs and the HPUra
molecule from which they evolved share the same level of
target selectivity in vivo in the intact cell.
Effects of MP-EMAU and HP-EMAU on murine staphylo-
coccal infection. Given their relatively high aqueous solubilities
and the potency of their bactericidal effects against the Smith
strain of S. aureus (Fig. 2B), we selected the two propyl deriv-
atives, MP-EMAU and HP-EMAU, for testing in a simple in
vivo lethal infection model employing the same organism (de-
tails of model appear in the Materials and Methods section).
Specifically, mice were infected by intraperitoneal injection of
a fixed, lethal dose of bacteria, and 15 min thereafter, groups
of 10 mice each were injected by the same route with (i) the
agent to be tested, (ii) vehicle, or (iii) vancomycin as a positive
control agent of known efficacy. Thereafter, each treatment
group was monitored over a 3-day period. The results, ex-
pressed as the number of mice surviving at 3 days after infec-
tion, are summarized in Table 5.
As expected, all of the animals that received 20 mg of van-
comycin per kg survived throughout the 3-day period, while 9
FIG. 2. Bactericidal activities of N-3 methoxyalkyl- and hydroxyalkyl-
EMAUs against S. aureus (Smith strain). Each of the four agents was tested, as
indicated, at its MIC and at four times (43) its MIC. The MICs of the agents for
this strain were as follows: HE-EMAU, 8 mg/ml; ME-EMAU, 16 mg/ml; HP-
EMAU, 8 mg/ml; and MP-EMAU, 8 mg/ml. (A) Activities of HE-EMAU and
ME-EMAU. (B) Activities of HP-EMAU and MP-EMAU.
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of the 10 control mice that received only vehicle died. Simi-
larly, all animals treated with HP-EMAU at a dose of 10 mg/kg
survived, and 7 of 10 animals treated with half that dose
(5 mg/kg) survived. After they were treated with MP-EMAU at
10 mg/kg, only 5 of 10 animals survived, and for those treated
at 5 mg/kg, survival (20%) was barely distinguishable from that
seen for animals in the vehicle (control) group (10%).
What is the significance of this in vivo protective effect of
HP-EMAU and MP-EMAU? This so-called “furry test tube”
infection model in which animals are infected and treated in
the same, intraperitoneal, compartment, is one of the simplest
infection models available for use in antibiotic testing. We
selected this specific model in an effort simply to “prove prin-
ciple” of antibiotic potential, reasoning that any candidate
agent which failed to display efficacy in this system was unlikely
to show efficacy in a more valid, pharmacokinetically complex
model exploiting infection at one site and administration of
agent at a different enteral or parenteral site. These prelimi-
nary results strongly suggest that the N-3-substituted AUs,
indeed, have considerable potential as antiinfectives—a poten-
tial which we intend to probe further with experiments em-
ploying more relevant infection models. To achieve this goal
we presently are evaluating, in mice, the basic pharmacokinet-
ics of HP-EMAU to permit its rational parenteral and oral
application, and we are continuing to devise even-more-soluble
and -potent AU derivatives through further manipulation of
both the ring N-3 substituent of the base-pairing domain and
substituents of the aryl ring.
Potential of pol III as an antibiotic target. Like DNA topo-
isomerase, the target of the highly effective fluoroquinolones,
pol III is an essential, rate-limiting component of the bacterial
DNA replication machinery (10, 15, 22). Given the essential,
replication-specific function of pol III and the results pre-
sented above for the AU class of pol III-specific inhibitors, we
propose that the development of pol III-specific antibiotics is
feasible. We are presently pursuing this proposition with two
approaches. The first, which is noted above, is to continue
pursuit of the anti-infective potential of our pol III-specific AU
platform compounds. The second is to identify and charac-
terize novel pol III-targeted molecules by exploiting high-
throughput screening of other, unrelated compounds for ac-
tivity in vitro against both the polC-specific pol III of the low
G1C content gram-positive organisms and the dnaE-specific
pol III of relevant gram-negative pathogens.
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TABLE 5. Effects of MP-EMAU and HP-EMAU on lethal
infection of mice by S. aureusa
Treatment used
(mg/kg)
No. of survivors at 3 days
postinfection (total
no. treated)
Vehicleb only ..................................................................... 1 (10)
Vancomycin (20) ............................................................... 10 (10)
HP-EMAU (10) ................................................................ 10 (10)
HP-EMAU (5) .................................................................. 7 (10)
MP-EMAU (10)................................................................ 5 (10)
MP-EMAU (5).................................................................. 2 (10)
a Intraperitoneal infection followed by a single intraperitoneal injection of
drug or drug vehicle; see the Materials and Methods section for experimental
details.
b Saline for vancomycin and 10% DMSO:90% peanut oil for EMAU deriva-
tives.
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